Dashboard
Manage Tickers

REGN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nasdaq-100-hits-26000-gold-falls-below-4000-whats-moving-markets-tuesday
Nasdaq 100 Hits 26,000, Gold Falls Below $...
10/28/2025 17:23:51

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech...

wayfair-qorvo-celestica-united-parcel-service-regeneron-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday
Wayfair, Qorvo, Celestica, United Parcel S...
10/28/2025 14:14:02

regenerons-q3-earnings-outperform-expectations-with-dupixent-strength-balancing-eylea-weakness
Regeneron's Q3 Earnings Outperform Expecta...
10/28/2025 13:13:27

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

regeneron-pharmaceuticals-q3-adj-eps-1183-beats-959-estimate-sales-3754b-beat-3585b-estimate
Regeneron Pharmaceuticals Q3 Adj. EPS $11....
10/28/2025 10:30:38

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $11.83 per share which beat the analyst consensus estima...

a-preview-of-regeneron-pharmaceuticalss-earnings
A Preview Of Regeneron Pharmaceuticals's E...
10/27/2025 15:01:00

heres-how-much-1000-invested-in-regeneron-pharmaceuticals-20-years-ago-would-be-worth-today
Here's How Much $1000 Invested In Regenero...
10/20/2025 16:14:58

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times
FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

regenerons-libtayo-wins-positive-european-medicines-agency-opinion-for-high-risk-skin-cancer-treatment-after-surgery-and-radiation
Regeneron's Libtayo Wins Positive European...
10/17/2025 11:32:55

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency's (EMA) Committee for Medi...

Core News & Articles
FDA Awards First-Ever National Priority Vo...
10/16/2025 21:27:26

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

eyepoint-pharmaceuticals-raises-capital-as-it-advances-lead-product-to-pivotal-study
EyePoint Pharmaceuticals Raises Capital As...
10/15/2025 15:01:34

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

regeneron-to-share-new-oncology-data-at-esmo-2025-highlighting-patient-friendly-libtayo-every-6-week-dosing
Regeneron to Share New Oncology Data at ES...
10/15/2025 11:04:44

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its advancing oncology pipeline will be...

canaccord-genuity-maintains-buy-on-regeneron-pharmaceuticals-maintains-850-price-target
Canaccord Genuity Maintains Buy on Regener...
10/14/2025 14:10:31

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $850 price ...

regenerons-gene-therapy-shows-significant-gains-in-genetic-hearing-loss
Regeneron's Gene Therapy Shows Significant...
10/13/2025 17:24:21

Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some part...

citigroup-maintains-buy-on-regeneron-pharmaceuticals-raises-price-target-to-660
Citigroup Maintains Buy on Regeneron Pharm...
10/13/2025 15:57:14

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fro...

reported-sunday-regenerons-db-oto-gene-therapy-yields-sustained-hearing-restoration-and-speech-perception-gains-in-otof-related-hearing-loss
Reported Sunday, Regeneron's DB-OTO Gene T...
10/13/2025 06:39:46

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal ...

forecasting-the-future-9-analyst-projections-for-regeneron-pharmaceuticals
Forecasting The Future: 9 Analyst Projecti...
10/10/2025 18:01:09

morgan-stanley-maintains-overweight-on-regeneron-pharmaceuticals-lowers-price-target-to-756
Morgan Stanley Maintains Overweight on Reg...
10/10/2025 17:24:28

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the p...

regenerons-libtayo-gains-fda-approval-to-reduce-recurrence-risk-in-skin-cancer-patients
Regeneron's Libtayo Gains FDA Approval To ...
10/09/2025 17:59:58

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, b...

regeneron-pharma-says-fda-approves-pd-1-inhibitor-libtayo-as-adjuvant-treatment-for-adult-patients-with-cscc-at-high-risk-of-recurrence-after-surgery-and-radiation
Regeneron Pharma Says FDA Approves PD-1 In...
10/08/2025 18:33:42

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION